Skip to Content

Davabazaar in India Vision and Objective

Sun, 10/11/2009 - 14:34 — Bhekare

Davabazaar in India website is a Pharma Trade Portal which caters to end patients and their relatives, chemist and medical stores, pharmacist and other pharma workers, doctors and nursing homes, hospitals and medical institutions, pharmaceutical manufactures and allied service providers, trade and manufactures associations.

For patients and relatives we have Ask-the-Doctor medical forums, health blogs, chats and patient health communities.

Drug Index Software

Mon, 10/05/2009 - 15:58 — Correspondent

Very soon the drug index software will be available for download. This software and all further upgrades are available free of cost to chemist and medical doctors. Please register and get yourself verified. Pharmaceutical companies who wish to add their information should also register and get verified.

Correspondent's picture

Pharma Overview

Wed, 08/12/2009 - 00:24 — Correspondent

Pharmaceutical OverviewLast Updated: April 2009

Sector structure/Market size


The Indian pharmaceutical industry is driving product development and breaking new grounds in medicine research worldwide.


The Indian domestic pharmaceutical market is estimated to be US$ 10.76 billion in 2008 and is expected to grow at a high compound annual growth rate (CAGR) of 9.9 per cent till 2010 and thereafter at a CAGR of 9.5 per cent till 2015.

Correspondent's picture

Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave (Naltrexone SR/Bupropion SR)

Thu, 09/02/2010 - 21:30 — Correspondent

Contrave (naltrexone SR/bupropion SR), an investigational drug aimed at combination therapy to address both biological and behavioral drivers of obesity, will be developed and commercialized by Orexigen Therapeutics, Inc. and Takeda Pharmaceutical Company Limited in the USA, Canada and Mexico. The two drug firms have just signed an exclusive partnership for the North American area...

Correspondent's picture

Therapeutic Workshops To Highlight Opportunities In Biotech At 9th Annual BIO Investor Forum

Thu, 09/02/2010 - 18:30 — Correspondent

BIO today announced the preliminary set of speakers who will be featured on the Therapeutic Workshops during the 9th Annual BIO Investor Forum - a national meeting focused on investment trends and opportunities in the life-sciences with a focus on public and venture-stage growth companies...

Correspondent's picture

Eisai Announces The Start Of The First Clinical Study Of Ban2401, A Novel Monoclonal Antibody Targeting Neurotoxic Protofibrils

Thu, 09/02/2010 - 16:30 — Correspondent

Eisai Co., Ltd. (Headquarters: Tokyo, Japan, President & CEO: Haruo Naito, "Eisai") announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease...

Correspondent's picture

BRINAVESS™ (vernakalant) For Infusion Approved In The European Union For Rapid Conversion Of Recent Onset Atrial Fibrillation

Thu, 09/02/2010 - 16:30 — Correspondent

Merck (known as MSD outside the United States and Canada) (NYSE:MRK) and Cardiome Pharma Corp...

Correspondent's picture

Novartis Drug Tasigna® Approved In Switzerland After Fast-track Review For Treatment Of Patients With Newly Diagnosed Ph+ CML

Thu, 09/02/2010 - 15:30 — Correspondent

The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase...

Correspondent's picture

Roche Provides Update On FDA Application For T-DM1

Thu, 09/02/2010 - 15:30 — Correspondent

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned Roche will continue with its ongoing Phase III EMILIA registration study...

Correspondent's picture

Actavis Receives FDA Approval Of Atomoxetine HCl Capsules

Thu, 09/02/2010 - 14:30 — Correspondent

Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder (ADHD). Actavis intends to market Atomoxetine HCl in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg strengths...

Correspondent's picture

QRxPharma Announces Interim Analysis Of Final Pivotal Phase 3 Study For MoxDuo®IR

Thu, 09/02/2010 - 14:30 — Correspondent

QRxPharma (ASX: QRX and OTCQX: QRXPY) announced a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission. The analysis indicated the planned sample size of 140 patients has greater than 90% power to detect differences of analgesic effect, indicating there is no need to enrol additional patients...

Correspondent's picture

Agensys, An Affiliate Of Astellas, Announces Initiation Of Phase I Clinical Trial Of AGS-16M8F For Renal Cancer

Thu, 09/02/2010 - 14:30 — Correspondent

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing...

Correspondent's picture

Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results

Thu, 09/02/2010 - 14:30 — Correspondent

A recent study conducted by oculoplastic surgeon Charles Soparkar, M.D., Ph.D. (The Methodist Hospital, Houston, TX) utilizing a patent-pending formulation of zinc and phytase (trademarked as ZYTAZE™), demonstrated that increasing zinc levels by oral administration for 4 days prior to a planned injection of botulinum toxin improved efficacy and/or duration in 41 of 44 patients tested (93%)...

Correspondent's picture

ReVision's Fenretinide (RT-101) Reduced Incidence Of Choroidal Neovascularization By More Than 50 Percent In Patients With Geographic Atrophy

Thu, 09/02/2010 - 14:30 — Correspondent

ReVision Therapeutics Inc. announced that data from a Phase 2b trial show that fenretinide (RT-101) reduced the incidence of choroidal neovascularization (CNV, wet age related macular degeneration) by about 50 percent in patients with geographic atrophy (GA), the most advanced form of dry age related macular degeneration (AMD). The data, presented Monday by Alexander M. Eaton, M.D...

Correspondent's picture

Microplasmin Meets Primary Endpoint In Second Phase III Trial In VMA, Confirms Positive Findings Of First Trial

Thu, 09/02/2010 - 14:30 — Correspondent

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint...

Correspondent's picture

Nanobiotechnology To Fight Cancer And Other Illnesses

Thu, 09/02/2010 - 12:30 — Correspondent

Two new groundbreaking scientific papers by researchers at UC Santa Barbara demonstrate the synthesis of nanosize biological particles with the potential to fight cancer and other illnesses. The studies introduce new approaches that are considered "green" nanobiotechnology because they use no artificial compounds...

Correspondent's picture

Full Issue

Thu, 09/02/2010 - 01:30 — Correspondent

View the entire issue.

Correspondent's picture

Tygacil Label Updated To Reflect Risk Of Death In Some Patients

Thu, 09/02/2010 - 01:30 — Correspondent

The FDA has updated the label for Pfizer’s Tygacil to reflect an increased risk of death, following the results of a pooled analysis.

Correspondent's picture

Stromedix Gets Orphan Drug Status for STX-100

Thu, 09/02/2010 - 01:30 — Correspondent

The FDA has given Stromedix’s novel humanized monoclonal antibody, STX-100, orphan drug status for a second indication as a treatment for idiopathic pulmonary fibrosis (IPF).

Correspondent's picture

Pfizer Expands Neurology Pipeline With FoldRx Acquisition

Thu, 09/02/2010 - 01:30 — Correspondent

Pfizer has agreed to purchase FoldRx, which specializes in compounds to treat diseases caused by protein misfolding, and has a first-in-class candidate to treat a rare genetic neurodegenerative disorder.

Correspondent's picture

CMS Schedules November Meeting to Discuss Provenge Coverage

Thu, 09/02/2010 - 01:30 — Correspondent

As the Medicare debate over Dendreon’s Provenge continues, the Centers for Medicare & Medicaid Services (CMS) is convening a meeting to consider the evidence for coverage of the prostate cancer drug.

Correspondent's picture

Allergan to Pay $600 Million to Settle Botox Misbranding Claims

Thu, 09/02/2010 - 01:30 — Correspondent

Allergan has agreed to pay $600 million to the U.S. government and plead guilty to a misdemeanor misbranding charge to settle civil and criminal allegations that the company promoted its drug Botox for off-label uses.

Correspondent's picture

Matrixx Case Puts Much at Stake for Drugmakers, FDA

Thu, 09/02/2010 - 01:30 — Correspondent

As the Supreme Court prepares to hear arguments in a shareholder lawsuit against Matrixx Initiatives, the industry as a whole is bracing itself for a ruling that could dramatically increase the amount of information companies provide to the public and change the FDA’s role in monitoring drug safety.

Correspondent's picture

Botox Maker Allergan Agrees To Pay $600 Million And Pleads Guilty To Misdemeanor

Wed, 09/01/2010 - 23:30 — Correspondent

Allergan Inc., the makers of BOTOX (onabotulinumtoxinA) announced that it has agreed to pay US $600 million and to plead guilty to misdemeanor, thus reaching a resolution with the DOJ (US Department of Justice) regarding a previously reported Government investigation into the company's past sales and marketing practices related to specific therapeutic uses of BOTOX...

Correspondent's picture

Poor People Can Be Pushed Further Into Poverty By The Need To Buy Common Medicines

Wed, 09/01/2010 - 15:30 — Correspondent

A substantial proportion (up to 86%) of the population living in low and middle income countries would be pushed into poverty as a result of purchasing common life-saving medicines. These are the findings of a study by Laurens Niens from Erasmus University Rotterdam and colleagues and published in this week's PLoS Medicine...

Correspondent's picture

Bionovo Receives Positive Guidance From FDA On Menerba®

Wed, 09/01/2010 - 14:30 — Correspondent

Bionovo, Inc. (Nasdaq: BNVI, BNVID) announced that it has received positive guidance from the U.S. Food and Drug Administration (FDA) regarding the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate Menerba®. The FDA indicated its agreement with Bionovo's plan...

Correspondent's picture

BioMarin Receives Orphan Drug Designation From The FDA For BMN-701 For The Treatment Of Pompe Disease

Wed, 09/01/2010 - 14:30 — Correspondent

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease...

Correspondent's picture

Glenmark Announces The Discovery Of A Novel Chemical Entity 'GRC 17536', A TRPA1 Receptor Antagonist, A Potential First-in-Class Molecule Globally

Wed, 09/01/2010 - 14:30 — Correspondent

Glenmark Pharmaceuticals announced the discovery of a Novel Chemical Entity(NCE) 'GRC 17536'. The new NCE program is targeting TRPA1 receptor antagonists for pain and respiratory disorders...

Correspondent's picture

Naurex's Novel Antidepressant GLYX-13 Recognized As One Of Windhover's Top 10 Neuroscience Projects To Watch

Wed, 09/01/2010 - 14:30 — Correspondent

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch...

Correspondent's picture

GSK And Valeant Announce New U.S. FDA PDUFA Goal Date For Ezogabine

Wed, 09/01/2010 - 14:30 — Correspondent

GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010. The original goal date was 30 August 2010...

Syndicate content


Theme by Dr. Radut.